Market Summary
USD41.12-0.62
Market Closed-1.49%
ATRC Stock Price
ATRC RSI Chart
ATRC Valuation
ATRC Price/Sales (Trailing)
ATRC Profitability
ATRC Fundamentals
ATRC Revenue
ATRC Earnings
Price Action
52 Week Range
32.5159.61
(Low)(High)
Last 7 days
-7.9%
Last 30 days
-12.4%
Last 90 days
-14.1%
Trailing 12 Months
-1.4%
ATRC Financial Health
ATRC Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for ATRC
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-08-06 | Wirick Angela L | sold (taxes) | -297,081 | 57.23 | -5,191 | chief financial officer |
2023-08-04 | CARREL MICHAEL H | gifted | - | - | -1,250 | president, ceo, & director |
2023-07-26 | Dahlquist Karl S. | sold | -195,077 | 57.09 | -3,417 | chief legal officer |
2023-06-30 | Noznesky Justin J | acquired | 20,846 | 38.11 | 547 | chief mktg & strategy officer |
2023-06-30 | Seith Douglas J | acquired | 21,227 | 38.11 | 557 | chief operating officer |
2023-06-30 | Dahlquist Karl S. | acquired | 21,227 | 38.11 | 557 | chief legal officer |
2023-06-30 | CARREL MICHAEL H | acquired | 21,227 | 38.11 | 557 | president, ceo, & director |
2023-06-30 | Yount Deborah Lee | acquired | 17,149 | 38.11 | 450 | chief human resources officer |
2023-06-30 | Privitera Salvatore | acquired | 21,227 | 38.11 | 557 | chief technical officer |
2023-06-30 | Doraiswamy Vinayak | acquired | 21,227 | 38.11 | 557 | chief scientific officer |
Which funds bought or sold ATRC recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-21 | Baystate Wealth Management LLC | unchanged | - | 775 | 4,837 | -% |
2023-09-20 | BARCLAYS PLC | reduced | -24.01 | -108,000 | 1,025,000 | -% |
2023-08-22 | COMERICA BANK | new | - | 96,000 | 96,000 | 0.01% |
2023-08-21 | OSAIC HOLDINGS, INC. | added | 0.78 | 113,035 | 677,630 | -% |
2023-08-21 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | added | 2.55 | 511,428 | 2,823,340 | -% |
2023-08-18 | Legato Capital Management LLC | added | 39.62 | 495,253 | 1,242,640 | 0.17% |
2023-08-17 | Orion Portfolio Solutions, LLC | reduced | -6.03 | 393,699 | 3,700,120 | 0.04% |
2023-08-16 | Nuveen Asset Management, LLC | added | 41.24 | 19,635,300 | 48,430,300 | 0.02% |
2023-08-15 | GOLDMAN SACHS GROUP INC | added | 10.07 | 3,065,170 | 12,927,600 | -% |
2023-08-15 | LAZARD ASSET MANAGEMENT LLC | unchanged | - | 14,000 | 89,000 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of AtriCure
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 14, 2023 | alliancebernstein l.p. | 7.7% | 3,565,726 | SC 13G/A | |
| Feb 14, 2023 | alger associates inc | 3.8% | 1,755,398 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 9.44% | 4,389,815 | SC 13G/A | |
| Feb 03, 2023 | blackrock inc. | 8.0% | 3,735,766 | SC 13G/A | |
| Feb 03, 2023 | invesco ltd. | 7.2% | 3,367,324 | SC 13G/A | |
| Feb 14, 2022 | alger associates inc | 7.1% | 3,240,847 | SC 13G/A | |
| Feb 14, 2022 | alliancebernstein l.p. | 7.5% | 3,455,856 | SC 13G | |
| Feb 14, 2022 | price t rowe associates inc /md/ | 4.2% | 1,945,751 | SC 13G/A | |
| Feb 09, 2022 | vanguard group inc | 9.22% | 4,234,298 | SC 13G/A | |
| Feb 09, 2022 | invesco ltd. | 5.3% | 2,437,617 | SC 13G/A |
Recent SEC filings of AtriCure
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Aug 17, 2023 | 144 | Notice of Insider Sale Intent | |
| Aug 08, 2023 | 4 | Insider Trading | |
| Aug 08, 2023 | 4 | Insider Trading | |
| Jul 28, 2023 | 4 | Insider Trading | |
| Jul 26, 2023 | S-8 | Employee Benefits Plan | |
| Jul 26, 2023 | S-8 | Employee Benefits Plan | |
| Jul 26, 2023 | 144 | Notice of Insider Sale Intent | |
| Jul 26, 2023 | 10-Q | Quarterly Report | |
| Jul 25, 2023 | 8-K | Current Report | |
| Jul 03, 2023 | 4 | Insider Trading |
Peers (Alternatives to AtriCure)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
SYK | 108.3B | 19.5B | 3.38% | 36.58% | 39.99 | 5.57 | 10.36% | 30.30% |
ISRG | 101.2B | 6.7B | -0.75% | 50.83% | 71.05 | 15.19 | 11.75% | -0.66% |
BSX | 77.5B | 13.4B | 6.45% | 36.39% | 85 | 5.78 | 8.69% | 3.17% |
BDX | 71.3B | 19.0B | -4.29% | 12.66% | 44.09 | 3.79 | 0.46% | -5.24% |
EW | 42.3B | 5.7B | -8.22% | -17.24% | 30.48 | 7.49 | 5.64% | -4.53% |
| MID-CAP | ||||||||
PEN | 9.5B | 937.8M | -2.12% | 37.22% | 325.65 | 10.11 | 16.30% | 250.21% |
SWAV | 7.1B | 616.6M | -12.54% | -24.86% | 29.24 | 11.56 | 69.52% | 343.68% |
GMED | 5.1B | 1.1B | -6.10% | -12.07% | 24.23 | 4.65 | 12.63% | 50.85% |
IRTC | 2.6B | 452.1M | -21.20% | -33.94% | -26.32 | 5.78 | 24.99% | 24.09% |
TNDM | 1.3B | 790.3M | -27.09% | -56.49% | -5.97 | 1.69 | 3.21% | -1604.53% |
| SMALL-CAP | ||||||||
ATEC | 1.6B | 421.8M | -15.15% | 56.11% | -9.32 | 3.69 | 44.49% | -2.43% |
AVNS | 947.4M | 780.7M | -7.75% | -9.65% | -26.32 | 1.21 | 4.68% | -510.17% |
CSII | 839.3M | 239.8M | 0.70% | 0.15% | -22.16 | 3.5 | -4.74% | -31.15% |
SILK | 609.7M | 162.9M | -27.67% | -61.65% | -11.53 | 3.74 | 42.67% | 12.82% |
AtriCure News
Returns for ATRC
Cumulative Returns on ATRC
14.4%
10-Year Cumulative Returns
14.3%
7-Year Cumulative Returns
3.1%
5-Year Cumulative Returns
1.8%
3-Year Cumulative Returns
Risks for ATRC
What is the probability of a big loss on ATRC?
90%
Probability that AtriCure stock will be more than 20% underwater in next one year
53.9%
Probability that AtriCure stock will be more than 30% underwater in next one year.
37.7%
Probability that AtriCure stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does ATRC drawdown profile look like?
Y-axis is the maximum loss one would have experienced if AtriCure was unfortunately bought at previous high price.
Drawdowns
Financials for AtriCure
Income Statement (Last 12 Months)
| Income Statement (Last 12 Months) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Revenue | 4.7% | 365,686,000 | 349,297,000 | 330,379,000 | 315,569,000 | 302,783,000 | 289,630,000 | 274,329,000 | 258,836,000 | 243,133,000 | 212,581,000 | 206,531,000 | 210,127,000 | 211,984,000 | 230,066,000 | 230,807,000 | 222,379,000 | 215,706,000 | 208,602,000 | 201,630,000 | 194,799,000 | 187,008,000 |
| Cost Of Revenue | 3.2% | 92,174,000 | 89,343,000 | 84,439,000 | 79,726,000 | 76,427,000 | 72,715,000 | 68,469,000 | 65,555,000 | 61,744,000 | 57,616,000 | 57,222,000 | 58,481,000 | 58,875,000 | 60,718,000 | 60,472,000 | 58,228,000 | 57,404,000 | 56,114,000 | 54,510,000 | 53,586,000 | 50,825,000 |
| Gross Profit | 5.2% | 273,512,000 | 259,954,000 | 245,940,000 | 235,843,000 | 226,356,000 | 216,915,000 | 205,860,000 | 193,281,000 | 181,389,000 | 154,965,000 | 149,309,000 | 151,646,000 | 153,109,000 | 169,348,000 | 170,335,000 | 164,151,000 | 158,302,000 | 152,488,000 | 147,120,000 | 141,213,000 | 136,183,000 |
| Operating Expenses | 1.4% | 298,297,000 | 294,255,000 | 288,609,000 | 286,878,000 | 167,999,000 | 159,975,000 | 150,655,000 | 143,077,000 | 233,845,000 | 199,629,000 | 193,542,000 | 193,702,000 | 199,811,000 | 212,604,000 | 203,457,000 | 184,554,000 | 176,116,000 | 165,505,000 | 164,247,000 | 157,868,000 | 153,637,000 |
| S&GA Expenses | 0.6% | 236,615,000 | 235,220,000 | 231,272,000 | 229,481,000 | 222,087,000 | 216,657,000 | 204,649,000 | 200,611,000 | 184,295,000 | 152,240,000 | 150,829,000 | 153,131,000 | 159,854,000 | 172,879,000 | 167,143,000 | 147,965,000 | 141,125,000 | 131,663,000 | 129,524,000 | 123,879,000 | 120,238,000 |
| R&D Expenses | 4.5% | 61,682,000 | 59,035,000 | 57,337,000 | 57,397,000 | 53,512,000 | 50,918,000 | 48,506,000 | 45,569,000 | 44,861,000 | 42,700,000 | 43,070,000 | 45,295,000 | 44,873,000 | 44,641,000 | 41,230,000 | 36,589,000 | 34,991,000 | 33,842,000 | 34,723,000 | 33,989,000 | 33,399,000 |
| EBITDA | 100.0% | - | -23,480,000 | -33,155,000 | -43,590,000 | 65,748,000 | 64,420,000 | 62,839,000 | 58,241,000 | -43,920,000 | -43,681,000 | -43,156,000 | -40,677,000 | -45,130,000 | -41,349,000 | -30,884,000 | - | - | - | - | - | - |
| EBITDA Margin | 100.0% | - | -0.07 | -0.10 | -0.14 | 0.22 | 0.22 | 0.23 | 0.23 | -0.18 | -0.21 | -0.21 | -0.19 | -0.21 | -0.18 | -0.13 | - | - | - | - | - | - |
| Interest Expenses | 11.0% | 6,240,000 | 5,622,000 | 4,986,000 | 4,508,000 | 4,633,000 | 4,729,000 | 4,918,000 | 5,029,000 | 4,812,000 | 4,846,000 | 4,885,000 | 4,948,000 | 4,829,000 | 4,477,000 | 4,111,000 | 4,174,000 | 4,307,000 | 4,649,000 | 4,607,000 | 3,857,000 | 3,187,000 |
| Earnings Before Taxes | 26.1% | -27,698,000 | -37,469,000 | -46,198,000 | -55,837,000 | 53,535,000 | 52,146,000 | 50,387,000 | 45,611,000 | -56,488,000 | -48,527,000 | -48,041,000 | -45,625,000 | -49,959,000 | -45,826,000 | -34,995,000 | -22,298,000 | -20,195,000 | -16,394,000 | -20,911,000 | -20,192,000 | -20,228,000 |
| EBT Margin | 100.0% | - | -0.11 | -0.14 | -0.18 | 0.18 | 0.18 | 0.18 | 0.18 | -0.23 | -0.23 | -0.23 | -0.22 | -0.24 | -0.20 | -0.15 | - | - | - | - | - | - |
| Net Income | 25.8% | -28,036,000 | -37,759,000 | -46,466,000 | -56,037,000 | 53,343,000 | 51,933,000 | 50,199,000 | 45,378,000 | -56,679,000 | -48,664,000 | -48,155,000 | -45,689,000 | -50,102,000 | -45,967,000 | -35,194,000 | -22,528,000 | -20,401,000 | -16,638,000 | -21,137,000 | -20,287,000 | -20,298,000 |
| Net Income Margin | 100.0% | - | -0.11 | -0.14 | -0.18 | 0.18 | 0.18 | 0.18 | 0.18 | -0.23 | -0.23 | -0.23 | -0.22 | -0.24 | -0.20 | -0.15 | - | - | - | - | - | - |
| Free Cashflow | 100.0% | - | -17,590,000 | -39,022,000 | -37,306,000 | -32,113,000 | -40,904,000 | -23,533,000 | -18,222,000 | -13,937,000 | -17,851,000 | -25,128,000 | -35,916,000 | -44,424,000 | -30,765,000 | -27,993,000 | - | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Assets | 1.9% | 594 | 583 | 585 | 582 | 587 | 585 | 615 | 613 | 701 | 700 | 715 | 708 | 704 | 528 | 558 | 561 | 343 | 338 | 357 | 272 | 271 |
| Current Assets | -0.1% | 238 | 238 | 215 | 212 | 206 | 200 | 196 | 196 | 236 | 298 | 307 | 296 | 292 | 127 | 143 | 138 | 147 | 155 | 175 | 88.00 | 87.00 |
| Cash Equivalents | -13.1% | 67.00 | 77.00 | 58.00 | 49.00 | 55.00 | 28.00 | 44.00 | 40.00 | 68.00 | 85.00 | 42.00 | 33.00 | 89.00 | 22.00 | 28.00 | 33.00 | 25.00 | 21.00 | 32.00 | 18.00 | 14.00 |
| Inventory | 13.4% | 55.00 | 49.00 | 46.00 | 44.00 | 41.00 | 41.00 | 39.00 | 39.00 | 38.00 | 36.00 | 35.00 | 34.00 | 33.00 | 32.00 | 29.00 | 28.00 | 24.00 | 24.00 | 22.00 | 22.00 | 22.00 |
| Net PPE | - | - | - | - | 39.00 | 36.00 | 33.00 | 31.00 | 30.00 | 30.00 | 28.00 | 28.00 | 29.00 | 30.00 | 32.00 | 33.00 | 31.00 | 28.00 | 27.00 | 27.00 | 28.00 | 28.00 |
| Goodwill | 0% | 235 | 235 | 235 | 235 | 235 | 235 | 235 | 235 | 235 | 235 | 235 | 235 | 235 | 235 | 235 | 236 | 105 | 105 | 105 | 105 | 105 |
| Liabilities | 2.7% | 132 | 128 | 129 | 132 | 131 | 122 | 132 | 125 | 316 | 309 | 302 | 290 | 287 | 300 | 311 | 303 | 102 | 99.00 | 107 | 108 | 111 |
| Current Liabilities | 14.3% | 71.00 | 62.00 | 58.00 | 58.00 | 56.00 | 47.00 | 56.00 | 54.00 | 67.00 | 58.00 | 49.00 | 45.00 | 38.00 | 39.00 | 50.00 | 44.00 | 39.00 | 35.00 | 40.00 | 34.00 | 27.00 |
| LT Debt, Non Current | -9.4% | 47.00 | 52.00 | 57.00 | 60.00 | 60.00 | 60.00 | 60.00 | 56.00 | 44.00 | 49.00 | 53.00 | 50.00 | 54.00 | 58.00 | 60.00 | 60.00 | 34.00 | 33.00 | 36.00 | 39.00 | 39.00 |
| Shareholder's Equity | 1.7% | 462 | 455 | 457 | 450 | 457 | 463 | 484 | 488 | 385 | 391 | 412 | 418 | 417 | 227 | 247 | 258 | 242 | 239 | 249 | 164 | 160 |
| Retained Earnings | -1.5% | -338 | -333 | -326 | -322 | -310 | -295 | -280 | -266 | -363 | -347 | -330 | -311 | -306 | -298 | -282 | -266 | -256 | -252 | -247 | -243 | -236 |
| Additional Paid-In Capital | 1.5% | 803 | 791 | 787 | 778 | 771 | 762 | 765 | 755 | 749 | 738 | 742 | 729 | 724 | 526 | 530 | 525 | 498 | 492 | 497 | 407 | 396 |
| Shares Outstanding | 0.2% | 47.00 | 47.00 | 47.00 | 46.00 | 46.00 | 46.00 | 46.00 | 45.00 | 45.00 | 45.00 | 45.00 | 44.00 | 40.00 | 39.00 | 40.00 | 38.00 | 37.00 | 37.00 | 34.00 | 34.00 | 33.00 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | -76.7% | -2.81 | -1.59 | -22.14 | -21.89 | -20.33 | -29.10 | -13.78 | -10.13 | -6.08 | -13.10 | -19.87 | -27.35 | -33.75 | -18.46 | -15.81 | -11.30 | -3.49 | -8.18 | -4.17 | -3.63 | -8.71 |
| Share Based Compensation | 4.8% | 32.00 | 30.00 | 29.00 | 29.00 | 29.00 | 29.00 | 28.00 | 27.00 | 26.00 | 25.00 | 23.00 | 21.00 | 20.00 | 18.00 | 18.00 | 18.00 | 18.00 | 17.00 | 16.00 | 15.00 | 15.00 |
| Cashflow From Investing | -68.9% | 16.00 | 53.00 | 44.00 | 38.00 | 16.00 | -20.36 | 24.00 | 20.00 | -13.19 | -109 | -156 | -156 | -107 | 4.00 | -2.15 | -70.37 | -61.34 | -70.14 | -85.40 | -13.51 | -15.51 |
| Cashflow From Financing | 54.5% | -0.95 | -2.08 | -7.06 | -6.53 | -8.39 | -7.43 | -7.64 | -3.70 | -1.74 | 187 | 189 | 184 | 205 | 16.00 | 14.00 | 97.00 | 76.00 | 78.00 | 100 | 16.00 | 17.00 |
ATRC Income Statement
2023-06-30Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Income Statement [Abstract] | ||||
| Revenue | $ 100,918 | $ 84,529 | $ 194,412 | $ 159,105 |
| Cost of revenue | 23,841 | 21,010 | 47,726 | 39,991 |
| Gross profit | 77,077 | 63,519 | 146,686 | 119,114 |
| Operating expenses: | ||||
| Research and development expenses | 17,438 | 14,791 | 32,765 | 28,420 |
| Selling, general and administrative expenses | 63,783 | 62,388 | 123,847 | 118,504 |
| Total operating expenses | 81,221 | 77,179 | 156,612 | 146,924 |
| Loss from operations | (4,144) | (13,660) | (9,926) | (27,810) |
| Other income (expense): | ||||
| Interest expense | (1,719) | (1,101) | (3,355) | (2,101) |
| Interest income | 961 | 76 | 1,836 | 192 |
| Other | (123) | (111) | 22 | (204) |
| Loss before income tax expense | (5,025) | (14,796) | (11,423) | (29,923) |
| Income tax expense | 93 | 45 | 171 | 101 |
| Net loss | $ (5,118) | $ (14,841) | $ (11,594) | $ (30,024) |
| Net (loss) income per share | ||||
| Basic net loss per common share (in usd per share) | $ (0.11) | $ (0.32) | $ (0.25) | $ (0.66) |
| Diluted net loss per common share (in usd per share) | $ (0.11) | $ (0.32) | $ (0.25) | $ (0.66) |
| Weighted average shares outstanding | ||||
| Weighted average shares outstanding—basic (in shares) | 46,266 | 45,692 | 46,187 | 45,610 |
| Weighted average shares outstanding—diluted (in shares) | 46,266 | 45,692 | 46,187 | 45,610 |
| Comprehensive income (loss): | ||||
| Unrealized gain (loss) on investments | $ 427 | $ (449) | $ 1,468 | $ (2,788) |
| Foreign currency translation adjustment | 36 | (430) | 19 | (608) |
| Other comprehensive income (loss) | 463 | (879) | 1,487 | (3,396) |
| Net loss | (5,118) | (14,841) | (11,594) | (30,024) |
| Comprehensive loss, net of tax | $ (4,655) | $ (15,720) | $ (10,107) | $ (33,420) |
ATRC Balance Sheet
2023-06-30Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 67,240 | $ 58,099 |
| Short-term investments | 59,785 | 63,014 |
| Accounts receivable, less allowance for credit losses of $230 | 48,362 | 42,693 |
| Inventories | 55,409 | 45,931 |
| Prepaid and other current assets | 7,179 | 5,477 |
| Total current assets | 237,975 | 215,214 |
| Long-term investments | 7,598 | 51,509 |
| Property and equipment, net | 40,540 | 38,833 |
| Operating lease right-of-use assets | 4,353 | 3,787 |
| Intangible assets, net | 67,383 | 39,339 |
| Goodwill | 234,781 | 234,781 |
| Other noncurrent assets | 1,541 | 1,985 |
| Total assets | 594,171 | 585,448 |
| Current liabilities: | ||
| Accounts payable | 23,709 | 19,898 |
| Accrued liabilities | 31,986 | 33,022 |
| Current maturities of debt and leases | 15,715 | 5,472 |
| Total current liabilities | 71,410 | 58,392 |
| Long-term debt | 47,047 | 56,834 |
| Finance lease liabilities | 8,614 | 9,147 |
| Operating lease liabilities | 3,458 | 3,095 |
| Other noncurrent liabilities | 1,220 | 1,226 |
| Total liabilities | 131,749 | 128,694 |
| Commitments and contingencies (Note 9) | ||
| Stockholders’ Equity: | ||
| Common stock, $0.001 par value, 90,000 shares authorized and 47,352 and 46,563 issued and outstanding | 47 | 47 |
| Additional paid-in capital | 803,197 | 787,422 |
| Accumulated other comprehensive loss | (2,609) | (4,096) |
| Accumulated deficit | (338,213) | (326,619) |
| Total stockholders’ equity | 462,422 | 456,754 |
| Total liabilities and stockholders’ equity | $ 594,171 | $ 585,448 |
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.